Joel Marcus
Founder & CEO @ Alexandria Real Estate Equities
Pasadena, United States
Joel Marcus is a Series B investor at Alexandria Real Estate Equities in Pasadena focused on Biotechnology and Biopharma. Joel Marcus is the Executive Chairman of the Board of Directors and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations. Joel co-founded Alexandria in 1994 as a garage startup with a business plan, and $19 millionin Series capital and has led its growth into a publicly traded, investment-grade REIT with a total market capitalization of approximately $18 billion and dominant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland and Research Triangle. Joel also founded and leads Alexandria Venture Investments, the company’s strategic venture capital arm, which focuses on novel, breakthrough discoveries in biopharmaceuticals, diagnostics, research tools, agtech, digital health, and technology. In 2011, Joel co-founded the renowned Alexandria Summit, an invitation-only gathering of the world’s foremost visionaries from the biopharmaceutical, medical, academic, financial, philanthropic, advocacy and government communities, to address the most critical global healthcare challenges. Prior to co-founding Alexandria, Joel had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions, with a unique expertise in the biopharmaceutical industry. Joel was also a practicing Certified Public Accountant and Tax Manager with Arthur Young & Co., where he focused on the financing and taxation of REITs. Joel was one of the original architects and co-founders of Accelerator Life Science Partners, for which he serves on the board of directors. Mr. Marcus also serves on the boards of Applied Therapeutics Inc., Boragen Inc., Frequency Therapeutics, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), MeiraGTx Holdings plc (NASDAQ:MGTX), and Yumanity Therapeutics; the Foundation for the National Institutes of Health (FNIH), MassBio, and Scripps Research; and the Emily Krzyzewski Center, the National September 11 Memorial & Museum, the Navy SEAL Foundation, the Partnership for New York City, and Robin Hood. Additionally, he is a member of the MIT Corporation Visiting Committee for the Department of Biology.Joel is a recipient of the EY Entrepreneur Of The Year Award (Los Angeles – Real Estate). Joel completed his undergraduate and Juris Doctor degrees at the University of California, Los Angeles.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Joel Marcus invests in
Stages Joel Marcus invests in
Countries Joel Marcus invests in
Investment Focus
Industry
- Biotechnology 5 (63%)
- Biopharma 2 (25%)
- Health Care 2 (25%)
- Medical 1 (13%)
- Wellness 1 (13%)
Stage
- Series B 4 (50%)
- Series A 3 (38%)
- Funding Round 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TRex Bio
|
TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $50M / Jan 27, 2026 | |
|
TRex Bio
|
TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $84M / Series B / Nov 13, 2024 | |
AltPep
|
AltPep Corp is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world’s most intractable diseases: amyloid diseases. | $52.9M / Series B / Jun 22, 2023 | |
IgGenix
|
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade. | $40M / Series B / Feb 06, 2023 | |
|
AltPep
|
AltPep Corp is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world’s most intractable diseases: amyloid diseases. | $23.2M / Series A / Jan 12, 2021 | |
Applied Therapeutics
|
Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. Ituses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs. | $25M / Series B / Feb 01, 2019 | |
|
Applied Therapeutics
|
Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. Ituses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs. | $6.1M / Series A / Feb 08, 2017 | |
BioRelix
|
BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 andis based in New Haven, Connecticut. | $25.8M / Series A / Jun 11, 2007 |
Co-Investors
About Alexandria Real Estate Equities
Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry®, is the largest owner and pre-eminent first-in-class real estate investment trust focused principally on science-driven cluster formation. Alexandria is the leading provider of real estate to the life science industry, and has an outstanding 11 year trackrecord as a NYSE listed company with an approximate $5.2 billion total market capitalization (as of December 31, 2008).
Alexandria Real Estate Equities Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John J. Cox
Senior Vice President
|
|||
Steven Hash
Board of Director
|
|||
Daniel J. Ryan
Executive Vice President
|
|||
|
Hallie Kuhn
Vice President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Joel Marcus invest in?
Joel Marcus invests primarily in Biotechnology, Biopharma and Health Care startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Joel Marcus last invest?
The most recent investment recorded for Joel Marcus closed in Jan 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
